YKL-40: a new biomarker in cardiovascular disease?

Cardiovascular disease in the form of coronary artery disease is the most common cause of death in western countries. Early treatment with stabilizing drugs and mechanical revascularization by percutaneous coronary intervention or coronary bypass surgery has reduced the mortality significantly. But...

Full description

Saved in:
Bibliographic Details
Published inBiomarkers in medicine Vol. 4; no. 4; pp. 591 - 600
Main Authors Mathiasen, Anders Bruun, Henningsen, Kristoffer Mads Aaris, Harutyunyan, Marina Jurjevna, Mygind, Naja Dam, Kastrup, Jens
Format Journal Article
LanguageEnglish
Published England Future Medicine Ltd 01.08.2010
Subjects
Adipokines
Biomarkers
Biomarkers - metabolism
Cardiovascular disease
Cardiovascular diseases
Cardiovascular Diseases - diagnosis
Cardiovascular Diseases - metabolism
Care and treatment
Chitinase-3-Like Protein 1
Coronary artery bypass
Development and progression
Diagnosis
Glycoproteins
Glycoproteins - metabolism
Health aspects
Humans
Lectins - metabolism
Medical prognosis
Medical treatment
Physiological aspects
Prognosis
Proteins
Denmark
Online AccessGet full text

Cover

More Information
Summary:Cardiovascular disease in the form of coronary artery disease is the most common cause of death in western countries. Early treatment with stabilizing drugs and mechanical revascularization by percutaneous coronary intervention or coronary bypass surgery has reduced the mortality significantly. But in spite of improved treatments, many patients are still plagued by a high frequency of angina symptoms, hospitalizations and a poor prognosis. There is a need for new independent or supplementary biomarkers that can help to predict cardiovascular disease and cardiovascular events earlier and more precisely, and thus accompany existing biomarkers in both primary and secondary cardiovascular prevention. One such potential new biomarker is the protein YKL-40. As an independent biomarker in both cardiovascular diseases and noncardiovascular diseases, current evidence suggests YKL-40 to be most useful as a marker of disease severity, prognosis and short survival. However, future studies will evaluate whether YKL-40 can be used for monitoring of the treatment effect in different patient populations with a distinct disease diagnosis. In this article we explore present knowledge on YKL-40 as a biomarker in cardiovascular disease.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1752-0363
1752-0371
DOI:10.2217/bmm.10.58